Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Agalsidase→

Agalsidase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
104138-64-9
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human alpha-galactosidase Aenzyme replacement therapy (ERT) biologic
Mechanism of action
Provides exogenous alpha-galactosidase A activity to hydrolyse globotriaosylceramide (GL-3) and related glycosphingolipid substrates that accumulate because of deficient endogenous enzyme activity in Fabry disease. Agalsidase alfa and agalsidase beta are distinct recombinant products; the exact product should be identified before product-specific use is assigned.
Indications / reported uses
  • Long-term enzyme replacement therapy for patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency); dosing, age eligibility and product information are specific to agalsidase alfa or beta

Sources: EMA EPAR — Fabrazyme (agalsidase beta) · EMA EPAR — Replagal (agalsidase alfa) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Agalsidase Environmental Risk Assessment (ERA) (the Agalsidase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.